We read with great interest the report of Zong et al. 1 in a recent issue of Leukemia dealing with the role of P-glycoprotein in imatinib resistance in vitro and in vivo. Using a transposonbased vector system we previously provided clear evidence that the specific knockdown of PgP using small interfering RNA (siRNA) resensitized imatinib-resitant cell lines to the growth inhibitory and cytotoxic effects of imatinib. 2 Other groups underlined the importance of PgP for imatinib transport by showing that it eliminates imatinib from the intracellular space at concentrations ranging from 0.5 to 3 mg/ml. 3 Although recognizing their impressive in vivo data, the animal model does not reflect the situation in malignant diseases, as under the latter condition the cancerous cells in general acquired resistance under chemotherapy and therefore express very high levels pf PgP. In contrast, the authors used stem cells of wildtype animals expressing 'physiologic' levels of Mdr1a/Mdr1b and compared these cells with cells from knockout mice (Mdr1a/Mdr1b-null). Moreover, the controversial in vitro data might also reflect different experimental approaches, as an isolated overexpression as carried out by Ferrao et al 4 or by Zong et al.
1 might be far more artificial when compared to the use of cells which upregulated PgP due to long-term culture in the presence of low-dose doxorubicin (which in our opinion more closely reflects the in vivo situation of acquiered drug resistance). We would even argue that the genetic modification using retroviral vectors might substantionally modify genetic programs by insertional mutagenesis. Finally, it is in our opinion critical that the authors used a model employing the mouse homologue of the human MDR1 gene. Thus, the same sensitivity to Glivec might also be due to a different substrate affinity to the mouse homologue.
Considering these points we feel that our data using the specificity of an siRNA approach strongly argue for the participation of PgP in chemoresistance to the cytotoxic effects of imatinib. The letter by Rumpold et al. 1 raises several objections to our conclusion that inhibition of P-glycoprotein (P-gp) is not likely to improve the response to imatinib in chronic myelogenous leukemia (CML). Their argument is in part based on their previous results showing that downregulation of P-gp expression in K562 cells sensitized the cells to imatinib treatment in vitro. However, our data in K562 cells 3 and that of Ferrao et al. 4 show that overexpression of P-gp does not confer significant resistance to imatinib in K562 cells. Rumpold et al. argue that this discrepancy could be due to potential differences in the level of P-gp expression in their doxorubicin-selected K562 cells versus our K562 cells that were transduced with an MDR1 retroviral vector. While this may be true, it is unclear how the levels of P-gp expression in any of these cell lines compare to that seen in primary CML stem cells. For this reason, we used an in vivo model of murine CML in which imatinib resistance was assessed in stem cells from P-gp null mice. Our data showed that loss of P-gp expression had no effect on imatinib responses. 3 Rumpold et al. argue that CML cells from patients may express higher levels of P-gp than in the mouse model due to the effects of prior drug therapy in patients. However, a previous clinical study reported that low levels of MDR1 gene expression in CML blast cells was not a predictor of response to imatinib in patients with CML blast crisis. 5 In addition, a recent report showed that there was no significant difference in expression of P-gp in bone marrow cells from 15 patients who were imatinib responders versus 15 nonresponders. 6 Furthermore, we treated mice continuously for up to 5 weeks with imatinib, so there is no a priori reason to believe that selection for high P-gp expression would not also occur in the mouse model system. Lastly, Rumpold et al. question whether the murine Mdr1-like gene products may differ from the human P-gp with regard to imatinib efflux capacity. While there are no data to directly compare human and mouse P-gp efflux capacity for imatinib, it is clear that imatinib is an in vivo substrate for mouse P-gp. 7, 8 We believe the differences in imatinib resistance seen when comparing the K562 data by Rumpold et al. with our data in P-gp null mice is best explained by the possibility that CML stem cells express other ABC transporters that may provide a redundant efflux mechanism for imatinib. The lack of expression of these compensatory transporters in K562 cells could therefore explain the sensitizing effect of decreased expression of P-gp in K562 cells. For instance, we have shown that K562 cells do not express ABCG2 (unpublished data) while primary hematopoietic stem cells express significant levels. 9 Therefore, we stand by our conclusion that the use of selective P-gp inhibitors to sensitize CML stem cells to imatinib is not likely to be clinically useful. In the September issue of Leukemia, Gyan et al.
1 report on the expression of a mutant Rap1B cDNA in myelodysplastic syndromes (MDS). Specifically, they detect a cDNA with point mutations, as compared to the wild-type Rap1B gene, that cause two amino-acid substitutions (G12R and K42E). Unfortunately, the authors could not perform an analysis of genomic DNA, which would directly reveal the relation between the Rap1B gene and the mutant cDNA. Although they point out correctly that the encoded protein most likely constitutes an activated form of Rap1B protein, we hereby present strong evidence that the detected cDNA does not originate from mutation of the Rap1B gene on chromosome 12.
An alternative explanation can be offered invoking the existence of an expressed processed gene, which we have named hRap1B-retro, located on chromosome 5 q13.3 (GI: 51465008). As it is the case for all processed genes, 2 this retrogene was generated by a LINE-1 retrotransposon 3 from the mRNA of Rap1B gene. The nucleotide sequence of the fulllength coding region of hRap1B-retro differs only at three positions from that of the mother Rap1B gene (Figure 1) . Two of these changes are identical to the reported mutations (G12R and K42E; GGA-CGA and AAG-GAG, respectively), with the third mutation being a silent one (G77G; GGA-GGG). The latter corresponds to a region in the cDNA that was not analysed by the authors.
Direct evidence for expression of hRap1B-retro comes from analysis of full-length expressed cDNAs deposited in the NCBI database. Interestingly, three of the cDNAs were cloned from a Ramos Burkitt's lymphoma cell line (GIs: 50475494, 50474682, 50470789), one was isolated from a neuroblastoma cell line (GI: 50498405), and one from a placental library (GI: 50492447). These sequences map exactly onto the genomic DNA sequence on chromosome 5 ( Figure 1, Supplementary Figure 1) , revealing a structure of the hRap1B-retro gene with two exons (Figure 1,  Supplementary Figure 2) . As genomic sequences of processed genes are expected to lack intronic sequences, we set out to analyse this observed peculiarity closely. We found that the intron was created via LINE-1-mediated insertion of the SVA element into a preferred target site sequence (TTTT/AA) 4 present in hRap1B mRNA at 1304 (GI: 58219793). Since this intronic region is missing from the sequences of the five deposited in database cDNAs, it is evident that they represent transcribed and spliced sequences rather than contaminating genomic DNA.
In conclusion, we think that it is highly likely that the mutant Rap1B cDNA reported by the authors is actually derived from expression of the hRap1B-retro gene in the MDS cells. Whether this may have contributed to the development of MDS, and possibly other malignancies (i.e. Burkitt's lymphoma), will require a more extensive analysis of the encoded gene product. For example, it should be determined whether the protein is indeed more GTP-bound. We would like to remark that we also found processed Rap1 genes in the mouse genome (manuscript in preparation; Marlena Duchniewicz, Taisa Paluch, Fried Zwartkruis and Tomasz Zemojtel). It should be noted that the existence of a functional processed gene belonging to Ras family has been reported previously. Intriguingly, the human ERas encodes an activated (i.e. GTP-bound) version of Ras and was
